{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T05:38:38Z","timestamp":1789191518200,"version":"build-2803163510"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T00:00:00Z","timestamp":1770681600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T00:00:00Z","timestamp":1770681600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s10620-026-09729-5","type":"journal-article","created":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T17:49:20Z","timestamp":1770745760000},"page":"2896-2904","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Major Adverse Cardiovascular Events and VTE in Patients with IBD Taking Anti-TNF versus JAK Inhibitors: A Multicenter Cohort Analysis"],"prefix":"10.1007","volume":"71","author":[{"given":"Saqr","family":"Alsakarneh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Razan","family":"Aburumman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farah","family":"Khraisat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarek","family":"Odeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana G.","family":"Hashash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darrell S.","family":"Pardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis A.","family":"Farraye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,10]]},"reference":[{"key":"9729_CR1","first-page":"427","volume":"37","author":"S Alsakarneh","year":"2024","unstructured":"Alsakarneh S, Hassan K, Jaber F et al. The national burden of inflammatory bowel disease in the United States from 1990\u20132019: results from the Global Burden of Disease study database. Ann Gastroenterol. 2024;37:427\u2013435.","journal-title":"Ann Gastroenterol."},{"key":"9729_CR2","first-page":"527","volume":"37","author":"S Alsakarneh","year":"2024","unstructured":"Alsakarneh S, Ahmed M, Jaber F et al. Inflammatory bowel disease burden in the Middle East and North Africa Region: a comprehensive analysis of incidence, prevalence, and mortality from 1990\u20132019. Ann Gastroenterol. 2024;37:527\u2013535.","journal-title":"Ann Gastroenterol."},{"key":"9729_CR3","doi-asserted-by":"crossref","unstructured":"Yeshi K, Jamtsho T, Wangchuk P 2024. Current Treatments, Emerging Therapeutics, and Natural Remedies for Inflammatory Bowel Disease. Molecules. 29","DOI":"10.3390\/molecules29163954"},{"key":"9729_CR4","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1136\/flgastro-2023-102400","volume":"15","author":"S Honap","year":"2024","unstructured":"Honap S, Agorogianni A, Colwill MJ et al. JAK inhibitors for inflammatory bowel disease: recent advances. Frontline Gastroenterol. 2024;15:59\u201369.","journal-title":"Frontline Gastroenterol."},{"key":"9729_CR5","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1136\/gutjnl-2016-312912","volume":"66","author":"P Olivera","year":"2017","unstructured":"Olivera P, Danese S, Peyrin-Biroulet L. Next generation of small molecules in inflammatory bowel disease. Gut. 2017;66:199\u2013209.","journal-title":"Gut."},{"key":"9729_CR6","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1093\/ibd\/izae116","volume":"31","author":"S Alsakarneh","year":"2025","unstructured":"Alsakarneh S, Desai A, Kochhar GS, Farraye FA, Hashash JG. Treatment of Chronic Pouchitis With JAK Inhibitors: Results from A Large Multicenter Database. Inflamm Bowel Dis. 2025;31:597\u2013600.","journal-title":"Inflamm Bowel Dis."},{"key":"9729_CR7","first-page":"511","volume":"38","author":"F Hasan","year":"2025","unstructured":"Hasan F, Liaquat A, Raza A et al. Effectiveness of upadacitinib in ulcerative colitis patients with prior tofacitinib exposure: a systematic review and meta-analysis. Ann Gastroenterol. 2025;38:511\u2013518.","journal-title":"Ann Gastroenterol."},{"key":"9729_CR8","doi-asserted-by":"crossref","unstructured":"Alsakarneh S, Jaber F, Parajuli S et al 2024. Efficacy and Safety of Janus Kinase Inhibitors in Chronic Inflammatory Pouch Conditions: A Systematic Review and Meta-analysis. Am J Ther.","DOI":"10.1097\/MJT.0000000000001761"},{"key":"9729_CR9","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1080\/13543784.2018.1492547","volume":"27","author":"F D\u2019Amico","year":"2018","unstructured":"D\u2019Amico F, Fiorino G, Furfaro F, Allocca M, Danese S. Janus kinase inhibitors for the treatment of inflammatory bowel diseases: developments from phase I and phase II clinical trials. Expert Opin Investig Drugs. 2018;27:595\u2013599.","journal-title":"Expert Opin Investig Drugs."},{"key":"9729_CR10","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1056\/NEJMra1907607","volume":"385","author":"DC Baumgart","year":"2021","unstructured":"Baumgart DC, Le Berre C. Newer Biologic and Small-Molecule Therapies for Inflammatory Bowel Disease. N Engl J Med. 2021;385:1302\u20131315.","journal-title":"N Engl J Med."},{"key":"9729_CR11","first-page":"204","volume":"20","author":"P Sinh","year":"2024","unstructured":"Sinh P, Cross RK. Cardiovascular Comorbidities and Inflammatory Bowel Disease: Causes and Consequences. Gastroenterol Hepatol (N Y). 2024;20:204\u2013215.","journal-title":"Gastroenterol Hepatol (N Y)."},{"key":"9729_CR12","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/j.cgh.2023.09.033","volume":"22","author":"SS Mattay","year":"2024","unstructured":"Mattay SS, Zamani M, Saturno D et al. Risk of Major Adverse Cardiovascular Events in Immune-Mediated Inflammatory Disorders on Biologics and Small Molecules: Network Meta-Analysis. Clin Gastroenterol Hepatol. 2024;22:961\u201370.e12.","journal-title":"Clin Gastroenterol Hepatol."},{"key":"9729_CR13","doi-asserted-by":"publisher","first-page":"175628482110321","DOI":"10.1177\/17562848211032126","volume":"14","author":"JAM Sleutjes","year":"2021","unstructured":"Sleutjes JAM, van Lennep JER, van der Woude CJ, de Vries AC. Thromboembolic and atherosclerotic cardiovascular events in inflammatory bowel disease: epidemiology, pathogenesis and clinical management. Therap Adv Gastroenterol. 2021;14:17562848211032126.","journal-title":"Therap Adv Gastroenterol."},{"key":"9729_CR14","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.3748\/wjg.v26.i12.1231","volume":"26","author":"K Cheng","year":"2020","unstructured":"Cheng K, Faye AS. Venous thromboembolism in inflammatory bowel disease. World J Gastroenterol. 2020;26:1231\u20131241.","journal-title":"World J Gastroenterol."},{"key":"9729_CR15","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1053\/j.gastro.2014.01.042","volume":"146","author":"GC Nguyen","year":"2014","unstructured":"Nguyen GC, Bernstein CN, Bitton A et al. Consensus statements on the risk, prevention, and treatment of venous thromboembolism in inflammatory bowel disease: Canadian Association of Gastroenterology. Gastroenterology. 2014;146:835\u201348.e6.","journal-title":"Gastroenterology."},{"key":"9729_CR16","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.autrev.2013.06.002","volume":"13","author":"S Ben-Horin","year":"2014","unstructured":"Ben-Horin S, Kopylov U, Chowers Y. Optimizing anti-TNF treatments in inflammatory bowel disease. Autoimmun Rev. 2014;13:24\u201330.","journal-title":"Autoimmun Rev."},{"key":"9729_CR17","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.cgh.2024.06.050","volume":"23","author":"DI Fudman","year":"2025","unstructured":"Fudman DI, McConnell RA, Ha C, Singh S. Modern Advanced Therapies for Inflammatory Bowel Diseases: Practical Considerations and Positioning. Clin Gastroenterol Hepatol. 2025;23:454\u2013468.","journal-title":"Clin Gastroenterol Hepatol."},{"key":"9729_CR18","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1056\/NEJMoa2109927","volume":"386","author":"SR Ytterberg","year":"2022","unstructured":"Ytterberg SR, Bhatt DL, Mikuls TR et al. Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis. N Engl J Med. 2022;386:316\u2013326.","journal-title":"N Engl J Med."},{"key":"9729_CR19","unstructured":"U.S. Food and Drug Administration 2021. FDA requires warnings about the increased risk of serious heart-related events, cancer, blood clots, and death. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-requires-warnings-about-increased-risk-serious-heart-related-events-cancer-blood-clots-and-death?utm_medium=email&utm_source=govdelivery."},{"key":"9729_CR20","doi-asserted-by":"crossref","unstructured":"Qapaja T, Abu-Rumaileh M, Alsabbagh Alchirazi K et al. Biologics and Oral Small Molecules Are Not Associated With Increased Major Adverse Cardiovascular Events or Venous Thromboembolism in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2024.","DOI":"10.1093\/ibd\/izae267"},{"key":"9729_CR21","unstructured":"TriNetX. Accessed May 20, 2024. [Available from: https:\/\/trinetx.com\/."},{"key":"9729_CR22","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1111\/apt.18138","volume":"60","author":"A Desai","year":"2024","unstructured":"Desai A, Petrov J, Hashash JG et al. Use of glucagon-like peptide-1 receptor agonists for type 2 diabetes mellitus and outcomes of inflammatory bowel disease. Aliment Pharmacol Ther. 2024;60:620\u2013632.","journal-title":"Aliment Pharmacol Ther."},{"key":"9729_CR23","doi-asserted-by":"crossref","unstructured":"Alsakarneh S, Ahmed M, Azim S et al 2024. Risk of Small Intestine Cancer in Inflammatory Bowel Disease: A Propensity-Matched Study from a Large Multi-Center Database in the United States. Am J Gastroenterol","DOI":"10.14309\/ajg.0000000000002984"},{"key":"9729_CR24","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1111\/apt.70303","volume":"62","author":"S Alsakarneh","year":"2025","unstructured":"Alsakarneh S, Aburumman R, Bilal M et al. Primary Sclerosing Cholangitis in the Absence of Inflammatory Bowel Disease Increases the Risk of Colorectal Cancer: A Multi-Centre Propensity Score Matched Analysis. Aliment Pharmacol Ther. 2025;62:1212\u20131219.","journal-title":"Aliment Pharmacol Ther."},{"key":"9729_CR25","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1111\/apt.70139","volume":"62","author":"S Alsakarneh","year":"2025","unstructured":"Alsakarneh S, Al Ta\u2019ani O, Aburumman R et al. Risk of De Novo Inflammatory Bowel Disease in Patients With Psoriasis and Psoriatic Arthritis Treated With IL-17A Inhibitors: A Population-Based Study. Aliment Pharmacol Ther. 2025;62:72\u201376.","journal-title":"Aliment Pharmacol Ther."},{"key":"9729_CR26","doi-asserted-by":"publisher","first-page":"S31","DOI":"10.4103\/sja.SJA_543_18","volume":"13","author":"S Cuschieri","year":"2019","unstructured":"Cuschieri S. The STROBE guidelines. Saudi J Anaesth. 2019;13:S31\u2013S34.","journal-title":"Saudi J Anaesth."},{"key":"9729_CR27","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1093\/ibd\/izac131","volume":"29","author":"S Hutfless","year":"2022","unstructured":"Hutfless S, Jasper RA, Tilak A, Ghosh T, Kedia S, Liu S et al. A Systematic Review of Crohn\u2019s Disease Case Definitions in Administrative or Claims Databases. Inflammatory Bowel Diseases. 2022;29:705\u2013715.","journal-title":"Inflammatory Bowel Diseases."},{"key":"9729_CR28","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1111\/apt.12294","volume":"37","author":"H Yuhara","year":"2013","unstructured":"Yuhara H, Steinmaus C, Corley D, Koike J, Igarashi M, Suzuki T et al. Meta-analysis: the risk of venous thromboembolism in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2013;37:953\u2013962.","journal-title":"Aliment Pharmacol Ther."},{"key":"9729_CR29","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1007\/s40264-018-0651-5","volume":"41","author":"IC Scott","year":"2018","unstructured":"Scott IC, Hider SL, Scott DL. Thromboembolism with Janus Kinase (JAK) Inhibitors for Rheumatoid Arthritis: How Real is the Risk? Drug Saf. 2018;41:645\u2013653.","journal-title":"Drug Saf."},{"key":"9729_CR30","doi-asserted-by":"publisher","first-page":"106210","DOI":"10.1016\/j.intimp.2020.106210","volume":"80","author":"P Xin","year":"2020","unstructured":"Xin P, Xu X, Deng C et al. The role of JAK\/STAT signaling pathway and its inhibitors in diseases. Int Immunopharmacol. 2020;80:106210.","journal-title":"Int Immunopharmacol."},{"key":"9729_CR31","doi-asserted-by":"publisher","first-page":"1110765","DOI":"10.3389\/fbioe.2023.1110765","volume":"11","author":"Q Hu","year":"2023","unstructured":"Hu Q, Bian Q, Rong D et al. JAK\/STAT pathway: Extracellular signals, diseases, immunity, and therapeutic regimens. Front Bioeng Biotechnol. 2023;11:1110765.","journal-title":"Front Bioeng Biotechnol."},{"key":"9729_CR32","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/s41392-021-00791-1","volume":"6","author":"X Hu","year":"2021","unstructured":"Hu X, Li J, Fu M, Zhao X, Wang W. The JAK\/STAT signaling pathway: from bench to clinic. Signal Transduct Target Ther. 2021;6:402.","journal-title":"Signal Transduct Target Ther."},{"key":"9729_CR33","doi-asserted-by":"publisher","first-page":"C186","DOI":"10.1152\/ajpcell.00298.2022","volume":"325","author":"NM Valenzuela","year":"2023","unstructured":"Valenzuela NM. JAKinibs prevent persistent, IFN\u03b3-autonomous endothelial cell inflammation and immunogenicity. Am J Physiol Cell Physiol. 2023;325:C186-c207.","journal-title":"Am J Physiol Cell Physiol."},{"key":"9729_CR34","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.semarthrit.2016.03.004","volume":"46","author":"C Charles-Schoeman","year":"2016","unstructured":"Charles-Schoeman C, Gonzalez-Gay MA, Kaplan I et al. Effects of tofacitinib and other DMARDs on lipid profiles in rheumatoid arthritis: implications for the rheumatologist. Semin Arthritis Rheum. 2016;46:71\u201380.","journal-title":"Semin Arthritis Rheum."},{"key":"9729_CR35","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1002\/acr.23930","volume":"71","author":"DD Gladman","year":"2019","unstructured":"Gladman DD, Charles-Schoeman C, McInnes IB et al. Changes in Lipid Levels and Incidence of Cardiovascular Events Following Tofacitinib Treatment in Patients With Psoriatic Arthritis: A Pooled Analysis Across Phase III and Long-Term Extension Studies. Arthritis Care Res (Hoboken). 2019;71:1387\u20131395.","journal-title":"Arthritis Care Res (Hoboken)."},{"key":"9729_CR36","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1016\/j.jacl.2017.06.012","volume":"11","author":"R Wolk","year":"2017","unstructured":"Wolk R, Armstrong EJ, Hansen PR et al. Effect of tofacitinib on lipid levels and lipid-related parameters in patients with moderate to severe psoriasis. J Clin Lipidol. 2017;11:1243\u20131256.","journal-title":"J Clin Lipidol."},{"key":"9729_CR37","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.cgh.2019.04.059","volume":"18","author":"BE Sands","year":"2020","unstructured":"Sands BE, Taub PR, Armuzzi A et al. Tofacitinib Treatment Is Associated With Modest and Reversible Increases in Serum Lipids in Patients With Ulcerative Colitis. Clin Gastroenterol Hepatol. 2020;18:123\u201332.e3.","journal-title":"Clin Gastroenterol Hepatol."},{"key":"9729_CR38","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1016\/j.dld.2024.03.010","volume":"56","author":"PA Olivera","year":"2024","unstructured":"Olivera PA, Dignass A, Dubinsky MC et al. Preventing and managing cardiovascular events in patients with inflammatory bowel diseases treated with small-molecule drugs, an international Delphi consensus. Dig Liver Dis. 2024;56:1270\u20131280.","journal-title":"Dig Liver Dis."},{"key":"9729_CR39","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1136\/ard-2022-223050","volume":"82","author":"V Molander","year":"2023","unstructured":"Molander V, Bower H, Frisell T et al. Venous thromboembolism with JAK inhibitors and other immune-modulatory drugs: a Swedish comparative safety study among patients with rheumatoid arthritis. Ann Rheum Dis. 2023;82:189\u2013197.","journal-title":"Ann Rheum Dis."},{"key":"9729_CR40","doi-asserted-by":"crossref","unstructured":"Meissner Y, Sch\u00e4fer M, Albrecht K et al 2023. Risk of major adverse cardiovascular events in patients with rheumatoid arthritis treated with conventional synthetic, biologic and targeted synthetic disease-modifying antirheumatic drugs: observational data from the German RABBIT register. RMD Open. 9","DOI":"10.1136\/rmdopen-2023-003489"},{"key":"9729_CR41","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1053\/j.gastro.2020.01.001","volume":"158","author":"PA Olivera","year":"2020","unstructured":"Olivera PA, Lasa JS, Bonovas S, Danese S, Peyrin-Biroulet L. Safety of Janus Kinase Inhibitors in Patients With Inflammatory Bowel Diseases or Other Immune-mediated Diseases: A Systematic Review and Meta-Analysis. Gastroenterology. 2020;158:1554\u201373.e12.","journal-title":"Gastroenterology."},{"key":"9729_CR42","doi-asserted-by":"publisher","first-page":"5206","DOI":"10.1007\/s10620-022-07404-z","volume":"67","author":"BD Kochar","year":"2022","unstructured":"Kochar BD, Cheng D, Cai T, Ananthakrishnan AN. Comparative Risk of Thrombotic and Cardiovascular Events with Tofacitinib and Anti-TNF Agents in Patients with Inflammatory Bowel Diseases. Dig Dis Sci. 2022;67:5206\u20135212.","journal-title":"Dig Dis Sci."},{"key":"9729_CR43","doi-asserted-by":"crossref","unstructured":"Sandborn WJ, D\u2019Haens GR, Sands BE et al 2023. Tofacitinib for the Treatment of Ulcerative Colitis: An Integrated Summary of up to 7.8 Years of Safety Data from the Global Clinical Programme. J Crohns Colitis. 17: 338\u201351.","DOI":"10.1093\/ecco-jcc\/jjac141"},{"key":"9729_CR44","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1111\/apt.16073","volume":"52","author":"VER Asscher","year":"2020","unstructured":"Asscher VER, Biemans VBC, Pierik MJ, Dijkstra G, L\u00f6wenberg M, van der Marel S et al. Comorbidity, not patient age, is associated with impaired safety outcomes in vedolizumab- and ustekinumab-treated patients with inflammatory bowel disease-a prospective multicentre cohort study. Aliment Pharmacol Ther. 2020;52:1366\u20131376.","journal-title":"Aliment Pharmacol Ther."}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-026-09729-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10620-026-09729-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-026-09729-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T11:54:10Z","timestamp":1786017250000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10620-026-09729-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,10]]},"references-count":44,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["9729"],"URL":"https:\/\/doi.org\/10.1007\/s10620-026-09729-5","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,10]]},"assertion":[{"value":"9 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflicts of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}